KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)
Public ClinicalTrials.gov record NCT03065244. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Kawasaki disease (KD) is a self-limited illness that affects the heart blood vessels (coronary arteries) of infants and children and is now the most common cause of acquired heart disease in children. A mixture of proteins from human blood (Intravenous immunoglobulin, IVIG) is a treatment that reduces the rate of the major complication of the disease: a bulging of the wall of the coronary arteries called an aneurysm. However, 10-20% of children are resistant to this treatment and the fever returns. These children have the highest rates of aneurysm formation and thus should be treated aggressively. Unfortunately, there are no guidelines for the best secondary treatment for these resistant patients because the problem has never been adequately studied. Most physicians choose either a second infusion of IVIG or an engineered antibody called infliximab that inactivates a molecule that promotes inflammation. This trial will randomize (assign by chance like the flip of a coin) IVIG-resistant patients to receive either a second IVIG infusion or infliximab and the response to treatment will be compared to learn which treatment stops the fever the fastest. In addition, parents and caregivers will provide observations about their child's response to the different treatments.
Study identification
- NCT ID
- NCT03065244
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 105 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Up to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 16, 2017
- Primary completion
- Aug 30, 2020
- Completion
- Nov 1, 2020
- Last update posted
- Dec 2, 2021
2017 – 2020
United States locations
- U.S. sites
- 29
- U.S. states
- 20
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB Children's of Alabama | Birmingham | Alabama | 35233 | — |
| Arkansas Children's Hospital | Little Rock | Arkansas | 72202 | — |
| University of California San Diego | La Jolla | California | 92093 | — |
| Memorial Care | Long Beach | California | 90806 | — |
| Children's Hospital Los Angeles | Los Angeles | California | 90027 | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90095 | — |
| Harbor-UCLA Medical Center | Los Angeles | California | 90502 | — |
| UCSF Benioff Children's Hospital-Oakland | Oakland | California | 94609 | — |
| Children's Hospital of Orange County | Orange | California | 92868 | — |
| UCSF Benioff Children's Hospital-San Francisco | San Francisco | California | 94920 | — |
| Cedar-Sinai Medical Center | West Hollywood | California | 94305 | — |
| Children's Hospital of Colorado | Aurora | Colorado | 80045 | — |
| Children's National Health SYstem | Washington D.C. | District of Columbia | 20010 | — |
| Children's Healthcare of Atlanta | Atlanta | Georgia | 30322 | — |
| Comer Children's Hospital | Chicago | Illinois | 60637 | — |
| Riley Children's Health Indiana University School of Medicine | Indianapolis | Indiana | 46202 | — |
| Boston Children's hospital | Boston | Massachusetts | 02115 | — |
| Children's Hospital of Michigan | Detroit | Michigan | 48201 | — |
| Children's Mercy Kansas Ciry | Kansas City | Missouri | 64108 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Maria Fareri Children's Hospital | Valhalla | New York | 10595 | — |
| Nationwide Children's Hospital | Columbus | Ohio | 43205 | — |
| UPMC Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania | 15224 | — |
| University of South Dakota Sanford School of Medicine | Sioux Falls | South Dakota | 57105 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Children's Medical Center of Dallas | Dallas | Texas | 75235 | — |
| Texas Children's Hospital | Houston | Texas | 77030 | — |
| Primary Care University of Utah | Salt Lake City | Utah | 84113 | — |
| Seattle Children's | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03065244, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2021 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03065244 live on ClinicalTrials.gov.